Redeye: Calliditas Therapeutics: Well-positioned late-stage orphan play

We are initiating coverage of Calliditas Therapeutics, a late-stage orphan drug company set to start a Phase III with lead project Nefecon for IgA nephropathy. We see a good case in the stock going forward, with strong sales potential and above-average probability of success. Fair value in our Base Case is SEK 70 per share.

Read more and download the initial analysis: http://bit.ly/2zv0S8Z

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/